Skip to main content

Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ)

SHZ Healthcare Drug Manufacturers - Specialty & GenericView data quality →
51.2Fair

ValueMarkers Composite Index

Top 37%#28,203 of 44,707

DCF data not available

Piotroski
6/9
Neutral
Beneish
-1.61
High Risk
Altman
2.78
Grey Zone
DCF Value
-
N/A
ROIC
2.9%
Low
P/E
36.0
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) — VMCI valuation read

Across 120 indicators, Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) lands at VMCI 51/100. The Healthcare sector median is 50, so the 1-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 300636.SZ in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 300636.SZ trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 0.4x leaves covenant headroom for 300636.SZ on the trailing balance sheet.

300636.SZ fell 3.0% over the trailing 7 days, with a +6.9% read on a 30-day basis.

Jiangxi Synergy Pharmaceutical Co., Ltd. manufactures and sells APIs worldwide. It offers APIs, liquid crystal compounds, and intermediates. Jiangxi Synergy Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Yichun, the People's Republic of China.

CEO: Zhengwei Pang1,362 employeesCNwww.jxsynergy.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 300636.SZ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.